12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DEX-M74: Phase I started

Researchers at NIH's National Human Genome Research Institute (NHGRI) began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate single doses of 3, 6 and 10 g DEX-M74...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >